<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03236662</url>
  </required_header>
  <id_info>
    <org_study_id>767161</org_study_id>
    <nct_id>NCT03236662</nct_id>
  </id_info>
  <brief_title>(-)- Epicatechin Becker Muscular Dystrophy</brief_title>
  <official_title>UCD0115B: An Open-label Extension Study of Purified Epicatechin to Improve Mitochondrial Function, Strength and Skeletal Muscle Exercise Response in Becker Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Craig McDonald, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cardero Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 48-week open-label extension of our initial proof-of-concept study (UCD0113) in&#xD;
      patients with Becker muscular dystrophy who participated in the earlier trial. This single&#xD;
      center study will enroll up to 10 adults who will receive the purified nutritional extract&#xD;
      (-)-epicatechin 100mg/day orally for 8 weeks. After screening visits, participants will be&#xD;
      enrolled in the study if they meet all inclusion criteria. They will be evaluated at&#xD;
      screening, baseline, and weeks 4, 8, 12, 24, 16 and 48. The main criterion for success of the&#xD;
      study will be presence of one or more biologic or strength and performance outcome measures&#xD;
      that yield a response magnitude that allows for sufficient power in a Phase II B study with a&#xD;
      sample size of 30 individuals.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Follistatin</measure>
    <time_frame>48 weeks</time_frame>
    <description>blood biomarker concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Myostatin</measure>
    <time_frame>48 weeks</time_frame>
    <description>blood biomarker concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Nitrates/ SNO</measure>
    <time_frame>48 weeks</time_frame>
    <description>blood biomarker concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma BNP</measure>
    <time_frame>48 weeks</time_frame>
    <description>blood biomarker concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Creatine Kinase</measure>
    <time_frame>48 weeks</time_frame>
    <description>blood biomarker concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma MMP-9</measure>
    <time_frame>48 weeks</time_frame>
    <description>blood biomarker concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma TNF-Alpha</measure>
    <time_frame>48 weeks</time_frame>
    <description>blood biomarker concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma TGF-Beta</measure>
    <time_frame>48 weeks</time_frame>
    <description>blood biomarker concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Follistatin:Myostain Ratio</measure>
    <time_frame>48 weeks</time_frame>
    <description>Ratio of plasma follistatin to plasma myostatin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graded Exercise Test Using a Recumbent Cycle Ergometer</measure>
    <time_frame>baseline and at 2-minute intervals</time_frame>
    <description>blood lactate measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minute Walk Test</measure>
    <time_frame>48 weeks</time_frame>
    <description>Measurements recorded will include 25-meter split times and total distance traveled.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory Proteomics</measure>
    <time_frame>48 weeks</time_frame>
    <description>Collection of plasma samples for proteomics analysis.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Becker Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(-)-epicatechin 50mg twice per day (100mg per day total dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(-)-Epicatechin</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prior participation in UCD0113 BMD epicatechin pilot study&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  Age 18 years to 70 years&#xD;
&#xD;
          -  Average to low daily physical activity&#xD;
&#xD;
          -  Ability to ambulate for 75 meters without assistive devices&#xD;
&#xD;
          -  Diagnosis of BMD confirmed by at least one the following:&#xD;
&#xD;
          -  Dystrophin immunofluorescence and/or immunoblot showing partial dystrophin deficiency,&#xD;
             and clinical picture consistent with typical BMD, or&#xD;
&#xD;
          -  Gene deletions test positive (missing one or more exons) of the dystrophin gene, where&#xD;
             reading frame can be predicted as 'in-frame', and clinical picture consistent with&#xD;
             typical BMD, or&#xD;
&#xD;
          -  Complete dystrophin gene sequencing showing an alteration (point mutation,&#xD;
             duplication, or other mutation resulting in a stop codon mutation) that can be&#xD;
             definitely associated with BMD, with a typical clinical picture of BMD, or&#xD;
&#xD;
          -  Positive family history of BMD confirmed by one of the criteria listed above in a&#xD;
             sibling or maternal uncle, and clinical picture typical of BMD.&#xD;
&#xD;
          -  Hematology profile within normal range&#xD;
&#xD;
          -  Baseline laboratory safety chemistry profile within normal range&#xD;
&#xD;
          -  No plan to change exercise regimen during study participation&#xD;
&#xD;
          -  Nutritional, herbal and antioxidant supplements taken with the intent of maintaining&#xD;
             or improving skeletal muscle strength or functional mobility have been discontinued at&#xD;
             least 2 weeks prior to screening (daily multivitamin use is acceptable).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently enrolled in another treatment clinical trial.&#xD;
&#xD;
          -  History of significant concomitant illness or significant impairment of renal or&#xD;
             hepatic function.&#xD;
&#xD;
          -  Use of regular daily aspirin or other medication with antiplatelet effects within 3&#xD;
             weeks of first dose of study medication.&#xD;
&#xD;
          -  Regular participation in vigorous exercise.&#xD;
&#xD;
          -  Symptomatic heart failure with cardiac ejection fraction &lt;25%&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 7, 2016</study_first_submitted>
  <study_first_submitted_qc>July 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2017</study_first_posted>
  <results_first_submitted>April 6, 2021</results_first_submitted>
  <results_first_submitted_qc>July 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 26, 2021</results_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Davis</investigator_affiliation>
    <investigator_full_name>Craig McDonald, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>BMD</keyword>
  <keyword>Becker muscular dystrophy</keyword>
  <keyword>epicatechin</keyword>
  <keyword>clinical trial</keyword>
  <keyword>neuromuscular disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 15, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT03236662/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 20, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT03236662/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>(-)-epicatechin 50mg twice per day (100mg per day total dose)&#xD;
(-)-Epicatechin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>(-)-epicatechin 50mg twice per day (100mg per day total dose)&#xD;
(-)-Epicatechin</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" lower_limit="52" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma Follistatin</title>
        <description>blood biomarker concentration</description>
        <time_frame>48 weeks</time_frame>
        <population>Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>(-)-epicatechin 50mg twice per day (100mg per day total dose)&#xD;
(-)-Epicatechin</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Follistatin</title>
          <description>blood biomarker concentration</description>
          <population>Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Myostatin</title>
        <description>blood biomarker concentration</description>
        <time_frame>48 weeks</time_frame>
        <population>Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>(-)-epicatechin 50mg twice per day (100mg per day total dose)&#xD;
(-)-Epicatechin</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Myostatin</title>
          <description>blood biomarker concentration</description>
          <population>Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Nitrates/ SNO</title>
        <description>blood biomarker concentration</description>
        <time_frame>48 weeks</time_frame>
        <population>Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>(-)-epicatechin 50mg twice per day (100mg per day total dose)&#xD;
(-)-Epicatechin</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Nitrates/ SNO</title>
          <description>blood biomarker concentration</description>
          <population>Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma BNP</title>
        <description>blood biomarker concentration</description>
        <time_frame>48 weeks</time_frame>
        <population>Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>(-)-epicatechin 50mg twice per day (100mg per day total dose)&#xD;
(-)-Epicatechin</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma BNP</title>
          <description>blood biomarker concentration</description>
          <population>Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Creatine Kinase</title>
        <description>blood biomarker concentration</description>
        <time_frame>48 weeks</time_frame>
        <population>Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>(-)-epicatechin 50mg twice per day (100mg per day total dose)&#xD;
(-)-Epicatechin</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Creatine Kinase</title>
          <description>blood biomarker concentration</description>
          <population>Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma MMP-9</title>
        <description>blood biomarker concentration</description>
        <time_frame>48 weeks</time_frame>
        <population>Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>(-)-epicatechin 50mg twice per day (100mg per day total dose)&#xD;
(-)-Epicatechin</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma MMP-9</title>
          <description>blood biomarker concentration</description>
          <population>Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma TNF-Alpha</title>
        <description>blood biomarker concentration</description>
        <time_frame>48 weeks</time_frame>
        <population>Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>(-)-epicatechin 50mg twice per day (100mg per day total dose)&#xD;
(-)-Epicatechin</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma TNF-Alpha</title>
          <description>blood biomarker concentration</description>
          <population>Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma TGF-Beta</title>
        <description>blood biomarker concentration</description>
        <time_frame>48 weeks</time_frame>
        <population>Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>(-)-epicatechin 50mg twice per day (100mg per day total dose)&#xD;
(-)-Epicatechin</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma TGF-Beta</title>
          <description>blood biomarker concentration</description>
          <population>Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Follistatin:Myostain Ratio</title>
        <description>Ratio of plasma follistatin to plasma myostatin</description>
        <time_frame>48 weeks</time_frame>
        <population>Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>(-)-epicatechin 50mg twice per day (100mg per day total dose)&#xD;
(-)-Epicatechin</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Follistatin:Myostain Ratio</title>
          <description>Ratio of plasma follistatin to plasma myostatin</description>
          <population>Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Graded Exercise Test Using a Recumbent Cycle Ergometer</title>
        <description>blood lactate measured</description>
        <time_frame>baseline and at 2-minute intervals</time_frame>
        <population>Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>(-)-epicatechin 50mg twice per day (100mg per day total dose)&#xD;
(-)-Epicatechin</description>
          </group>
        </group_list>
        <measure>
          <title>Graded Exercise Test Using a Recumbent Cycle Ergometer</title>
          <description>blood lactate measured</description>
          <population>Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>6-minute Walk Test</title>
        <description>Measurements recorded will include 25-meter split times and total distance traveled.</description>
        <time_frame>48 weeks</time_frame>
        <population>Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>(-)-epicatechin 50mg twice per day (100mg per day total dose)&#xD;
(-)-Epicatechin</description>
          </group>
        </group_list>
        <measure>
          <title>6-minute Walk Test</title>
          <description>Measurements recorded will include 25-meter split times and total distance traveled.</description>
          <population>Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Exploratory Proteomics</title>
        <description>Collection of plasma samples for proteomics analysis.</description>
        <time_frame>48 weeks</time_frame>
        <population>Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>(-)-epicatechin 50mg twice per day (100mg per day total dose)&#xD;
(-)-Epicatechin</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory Proteomics</title>
          <description>Collection of plasma samples for proteomics analysis.</description>
          <population>Due to lack of funding, only 2 participants could be enrolled. The number of evaluable patients was insufficient to perform analysis of this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>(-)-epicatechin 50mg twice per day (100mg per day total dose)&#xD;
(-)-Epicatechin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small number of subjects analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Craig McDonald, Professor and Chair</name_or_title>
      <organization>UC Davis Health</organization>
      <phone>(916) 734-4293</phone>
      <email>cmmcdonald@ucdavis.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

